Synapse - Robert Motzer

Results (1247)

Adjuvant therapy options in renal cell carcinoma — Targeting the metastatic cascade

Review

Fitzgerald, K. N.; Motzer, R. J.; Lee, C. H.
Nature Reviews Urology (2023)

Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations

Research Letter

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
European Urology (2023)

Fulltext@MSK | Save

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial

Journal Article

Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
Lancet (2023)

Fulltext@MSK | Save

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study

Journal Article

Choueiri, T. K.; Eto, M.; Motzer, R.; De Giorgi, U.; Buchler, T.; Basappa, N. S.; Méndez-Vidal, M. J.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
Lancet Oncology (2023)

Fulltext@MSK | Save

STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Choueiri, T. K.; Bedke, J.; Karam, J. A.; McKay, R. R.; Motzer, R. J.; Pal, S. M.; Suárez, C.; Uzzo, R.; Liu, H.; Burgents, J. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Meeting Abstract

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade

Meeting Abstract

Reese, S. W.; Jiang, H.; Kuo, F.; Wu, C. Y.; Vuong, L.; Mascareno, E.; Oparanozie, A.; Motzer, R. J.; Voss, M. H.; Reznik, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk

Meeting Abstract

Powles, T.; Motzer, R. J.; Albiges, L.; Suárez, C.; Schutz, F. A. B.; Heng, D. Y. C.; Chevreau, C.; Kanesvaran, R.; Gurney, H.; Wang, F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC)

Meeting Abstract

Choueiri, T. K.; Motzer, R. J.; Powles, T.; Burotto, M.; Apolo, A. B.; Escudier, B.; Tomita, Y.; McDermott, D. F.; Braun, D. A.; Han, C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save